Vimarsana
Biggest News Aggregation in the World

Page 7 - Per Plotnikof News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Per Plotnikof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Per Plotnikof Today - Breaking & Trending Today

Hans Lindeberg Appointed to Lead ALK North America - Vimarsana News

Hans Lindeberg Appointed to Lead ALK North America

/PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF) has appointed Hans Lindeberg as its new Senior Vice President of Commercial Operations in North...

Release date of three-month interim report (Q1) 2022 for ALK and audio cast - Vimarsana News

Release date of three-month interim report (Q1) 2022 for ALK and audio cast

03.05.2022 - On Thursday, 12 May 2022, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its three-month interim report (Q1) 2022. ALK will host a meeting for analysts and institutional investors that day at 1.30 pm (CEST) at which Management will review ...

Related Topics:
Jeppe IlkjPer Plotnikof
Clinical trial waiver in China opens door to 2022 registration filing for ALK's dust mite allergy tablet - Vimarsana News

Clinical trial waiver in China opens door to 2022 registration filing for ALK's dust mite allergy tablet

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Release date of annual report 2021 for ALK and audio cast - Vimarsana News

Release date of annual report 2021 for ALK and audio cast

On Tuesday, 8 February 2022, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its annual report for 2021. ALK will host a meeting for analysts and...

ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - Vimarsana News

ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients

/PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of...